493 related articles for article (PubMed ID: 30608114)
1. Targeting Type 1 Diabetes: Selective Approaches for New Therapies.
Sheehy DF; Quinnell SP; Vegas AJ
Biochemistry; 2019 Jan; 58(4):214-233. PubMed ID: 30608114
[TBL] [Abstract][Full Text] [Related]
2. Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes.
Kroger CJ; Clark M; Ke Q; Tisch RM
Front Immunol; 2018; 9():1891. PubMed ID: 30166987
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of carbonyl iron against multiple low-dose streptozotocin-induced diabetes in rodents.
Vujicic M; Saksida T; Mostarica Stojkovic M; Djedovic N; Stojanovic I; Stosic-Grujicic S
J Cell Physiol; 2018 Jun; 233(6):4990-5001. PubMed ID: 29215791
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulation and regeneration of islet Beta cells by cytokines in autoimmune type 1 diabetes.
Singh B; Nikoopour E; Huszarik K; Elliott JF; Jevnikar AM
J Interferon Cytokine Res; 2011 Oct; 31(10):711-9. PubMed ID: 21851268
[TBL] [Abstract][Full Text] [Related]
5. Anti-diabetic actions of carbon monoxide-releasing molecule (CORM)-A1: Immunomodulation and regeneration of islet beta cells.
Nikolic I; Saksida T; Vujicic M; Stojanovic I; Stosic-Grujicic S
Immunol Lett; 2015 May; 165(1):39-46. PubMed ID: 25839127
[TBL] [Abstract][Full Text] [Related]
6. DiaPep277® and immune intervention for treatment of type 1 diabetes.
Schloot NC; Cohen IR
Clin Immunol; 2013 Dec; 149(3):307-16. PubMed ID: 24090708
[TBL] [Abstract][Full Text] [Related]
7. Persistence of residual beta cells and islet autoimmunity during increasing duration of diabetes in NOD mice and experimental approaches toward reversing new-onset disease with bioactive peptides.
Reddy S; Cheung CC; Chai RC; Rodrigues JA
Ann N Y Acad Sci; 2008 Dec; 1150():171-6. PubMed ID: 19120289
[TBL] [Abstract][Full Text] [Related]
8. Prolactin as an Adjunct for Type 1 Diabetes Immunotherapy.
Hyslop CM; Tsai S; Shrivastava V; Santamaria P; Huang C
Endocrinology; 2016 Jan; 157(1):150-65. PubMed ID: 26512750
[TBL] [Abstract][Full Text] [Related]
9. Customized cell-based treatment options to combat autoimmunity and restore beta-cell function in type 1 diabetes mellitus: current protocols and future perspectives.
Fändrich F; Ungefroren H
Adv Exp Med Biol; 2010; 654():641-65. PubMed ID: 20217518
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy: Building a bridge to a cure for type 1 diabetes.
Bluestone JA; Buckner JH; Herold KC
Science; 2021 Jul; 373(6554):510-516. PubMed ID: 34326232
[TBL] [Abstract][Full Text] [Related]
11. Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitus.
Eldor R; Cohen IR; Raz I
Int Rev Immunol; 2005; 24(5-6):327-39. PubMed ID: 16318985
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulators: Cell savers.
DeWeerdt S
Nature; 2012 May; 485(7398):S4-5. PubMed ID: 22616095
[No Abstract] [Full Text] [Related]
13. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.
Vudattu NK; Herold KC
Expert Opin Biol Ther; 2014 Mar; 14(3):377-85. PubMed ID: 24517093
[TBL] [Abstract][Full Text] [Related]
14. Targeting dysfunctional beta-cell signaling for the potential treatment of type 1 diabetes mellitus.
Fenske RJ; Kimple ME
Exp Biol Med (Maywood); 2018 Mar; 243(6):586-591. PubMed ID: 29504478
[TBL] [Abstract][Full Text] [Related]
15. New prospects for immunotherapy at diagnosis of type 1 diabetes.
Pozzilli P; Leslie RD
Diabetes Metab Res Rev; 2009 May; 25(4):299-301. PubMed ID: 19405079
[TBL] [Abstract][Full Text] [Related]
16. Thymus and type 1 diabetes: an update.
Geenen V
Diabetes Res Clin Pract; 2012 Oct; 98(1):26-32. PubMed ID: 22717497
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus.
Ludwig B; Barthel A; Reichel A; Block NL; Ludwig S; Schally AV; Bornstein SR
Vitam Horm; 2014; 95():195-222. PubMed ID: 24559919
[TBL] [Abstract][Full Text] [Related]
18. Bioengineering strategies for inducing tolerance in autoimmune diabetes.
Baekkeskov S; Hubbell JA; Phelps EA
Adv Drug Deliv Rev; 2017 May; 114():256-265. PubMed ID: 28625830
[TBL] [Abstract][Full Text] [Related]
19. Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy.
Tian B; Hao J; Zhang Y; Tian L; Yi H; O'Brien TD; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2009 Jan; 87(2):198-206. PubMed ID: 19155973
[TBL] [Abstract][Full Text] [Related]
20. Immunopathogenesis and immunotherapeutic approaches to type 1A diabetes.
Azam A; Eisenbarth GS
Expert Opin Biol Ther; 2004 Oct; 4(10):1569-75. PubMed ID: 15461568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
